Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;31(8):1669-1673.
doi: 10.1080/09273948.2022.2098147. Epub 2022 Aug 1.

Ocular Inflammatory Complications of Treatment for Metastatic Melanoma

Andrew M Philip  1   2 , Stephen D Anesi  1   2 , C Stephen Foster  1   2   3 , Peter Chang  1   2
Affiliations

Ocular Inflammatory Complications of Treatment for Metastatic Melanoma

Andrew M Philip et al. Ocul Immunol Inflamm. 2023 Oct.

Abstract

Purpose: To characterize various ocular inflammatory complications arising from metastatic cutaneous melanoma therapies and their management.

Methods: Retrospective case series of patients who were referred to a tertiary uveitis practice for ophthalmic exam All patients received targeted metastatic cutaneous melanoma treatment, including BRAF/MEK inhibitors and various immunotherapies.

Results: 109 patients were identified, with 43 (39.4%) having 65 definitive instances of OIAE. Sixteen different OIAE were identified. Ipilimumab monotherapy and ipilimumab/nivolumab combination therapy were most commonly associated. Anterior uveitis was the most common OIAE (18/65, 27.7%). Thirty patients (69.8%) were managed with observation or topical steroid therapy. Only 4 patients required further therapies for OIAE, with one patient not attaining resolution.

Conclusions and relevance: While a broad range of OIAE was identified, most were not vision-threatening and did not require discontinuation of the associated therapy.

Keywords: BRAF; MEK; immunotherapies; metastatic melanoma; ocular inflammation.

Plain language summary

Question: What is the scope of ocular inflammatory complications from metastatic melanoma therapies?

Findings: In this retrospective chart review, 43 patients with definitive ocular inflammatory adverse effects(OIAE) were identified from 109 total patients on therapy for metastatic melanoma. Sixteen different OIAE were identified.Meaning: Ophthalmologists managing ocular complications from melanoma treatments should be aware of the broad, but usually mild, scope of possible complications.

PubMed Disclaimer

LinkOut - more resources